|1.||Cua, Daniel J: 3 articles (01/2014 - 12/2003)|
|2.||Iwakura, Yoichiro: 3 articles (10/2013 - 04/2008)|
|3.||Kolls, Jay K: 3 articles (12/2009 - 07/2005)|
|4.||McClanahan, Terrill K: 2 articles (05/2015 - 06/2007)|
|5.||Le Bert, Marc: 2 articles (10/2013 - 01/2011)|
|6.||Ryffel, Bernhard: 2 articles (10/2013 - 01/2011)|
|7.||Kamijima, Reiko: 2 articles (10/2013 - 04/2011)|
|8.||Takaishi, Mikiro: 2 articles (10/2013 - 04/2011)|
|9.||Nakajima, Kimiko: 2 articles (10/2013 - 04/2011)|
|10.||Vacher, Rachel: 2 articles (10/2013 - 01/2011)|
03/01/2013 - "The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. "
06/01/2007 - "Inhibition of IL-23p19 was effective in both prevention and treatment of active colitis. "
09/01/2006 - "In contrast, we describe in this study that newly created LacZ knockin mice deficient for IL-23 p19 were highly susceptible for the development of experimental T cell-mediated TNBS colitis and showed even more severe colitis than wild-type mice by endoscopic and histologic criteria. "
05/23/2008 - "Genetic and biochemical analyses show that IL-23p19 plays a central role in mediating bacteria-induced colitis in interleukin-10-deficient (IL-10(-/-)) mice. "
12/01/2013 - "IL-23 p19 vaccine is capable of downregulating inflammatory responses in chronic murine colitis, providing a novel therapeutic approach in Crohn's disease."
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
05/14/2015 - "Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL-23p19 subunit, in a three-part, randomized, placebo-controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoriasis to provide clinical proof that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects. "
10/01/2015 - "These results suggest that IL-23p19 is a key target for suppressing psoriasis."
03/01/2010 - "The decreased expression of VEGFR2 and VEGFR3 followed by the down-regulation of TNF-alpha and IL-23p19 may be contributory factors in the efficacy of PDL in stable plaque-type psoriasis."
03/01/2008 - "Increased IL-23 p19 mRNA levels were observed for both EN-like lesions of patients with BD and skin lesions of patients with psoriasis compared with normal individuals. "
04/01/2011 - "In this study, we characterized the effects of anti-mouse IL-17A, anti-mouse IL-12/23p40, and anti-mouse IL-23p19 Abs on the development of psoriasis-like lesions in K5.Stat3C transgenic mice. "
01/01/2014 - "IL-23p19 KO mice or normal wild type mice that survived primary LVS infection survived maximal doses of LVS secondary challenge. "
01/01/2014 - "Further, antibody responses in IL-23p19 KO mice were similar to those of normal wild type mice after LVS infection. "
01/01/2014 - "IL-23 p19 knockout mice exhibit minimal defects in responses to primary and secondary infection with Francisella tularensis LVS."
09/15/2011 - "SJL-IRF3 expression in RAW264.7 macrophage cells with or without TMEV infection decreased IL-23p19 promoter activity compared with B10S-IRF3. "
12/15/2009 - "Furthermore, a lack of efficient neutrophil recruitment to the liver is evident in both IL-23p19 KO and IL-17RA KO mice during LM infection. "
06/01/2013 - "Our data further indicate that tumor-secreted PGE2 through EP2 and EP4 receptors enhanced IL-23 p19 gene transcription through binding to the cAMP-response element in the p19 promoter. "
08/15/2012 - "Inhibition of IL-23p19 was shown to reduce the malignant potential of lesions established by MCA inoculation, whereas inhibition of IL-12/23p40 enhanced tumor outgrowth. "
01/01/2010 - "Furthermore we show that TRAMP C1 tumors growing in vivo spontaneously experience ER stress and that transcription of IL-6, IL-23p19, and TNF-α correlates with the in vivo ER stress response. "
02/01/2009 - "In conclusion, we show a characteristic gene expression profile combining markers associated with inhibition of anti-tumor immune response (Foxp3, IL-10), inhibition of apoptosis (survivin), and induction of the cytokines with protumoral activity as IL-12p40 and IL-23p19 (IL-23) in the colorectal tumor tissue but not in peripheral blood of patients."
06/01/2008 - "In this study, we show that lactic acid secreted by tumor cells enhances the transcription of IL-23p19 and IL-23 production in monocytes/macrophages and in tumor-infiltrating immune cells that are stimulated with TLR2 and 4 ligands. "
11/21/2011 - "Active immunization against IL-23p19 improves experimental arthritis."
11/21/2011 - "The aim of this study was to evaluate the effect of peptide-based vaccines targeting the IL-23p19 subunit in collagen-induced arthritis (CIA). "
01/01/2013 - "IL-23 dependent and independent stages of experimental arthritis: no clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis."
01/01/2013 - "IL-23p19 deficient mice have revealed a critical role of IL-23 in the development of experimental autoimmune diseases, such as collagen-induced arthritis (CIA). "
12/15/2003 - "Using gene-targeted mice lacking only IL-12 (p35-/-) or IL-23 (p19-/-), we show that the specific absence of IL-23 is protective, whereas loss of IL-12 exacerbates collagen-induced arthritis. "
|1.||Interleukin-17 (Interleukin 27)
|2.||Interleukin-23 (Interleukin 23)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||Messenger RNA (mRNA)
|7.||Interleukin-12 (IL 12)
|8.||adjuvant P40 (P 40)
|9.||Interleukin-10 (Interleukin 10)
|10.||Interleukin-4 (Interleukin 4)